Ask AI about LPATH
Quick answers generated from reviews and public information about this company.
AI-generated answers may be inaccurate. Check important details with the company directly.
0 Reviews
Italiano
No reviews
Questions & Answers
No questions yet — be the first to ask.
Sign in to post
Your text is saved — you'll come right back to post.
Don't have an account? Create one
News & Press
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
About LPATH
Lpath, Inc. is the category leader in the discovery and development of monoclonal antibodies that target (neutralize) bioactive lipids. The study of lipids (called lipidomics) is an emerging field of research that has already identified dozens of bioactive lipids that contribute to disease, with the promise of hundreds more as funding in the area continues to accelerate. Once a disease-causing lipid is identified, however, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2:tm: platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities.
- Website
- lpath.com
- [email protected]
